Correlation Between Blueprint Medicines and Syndax Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Blueprint Medicines and Syndax Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Blueprint Medicines and Syndax Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Blueprint Medicines Corp and Syndax Pharmaceuticals, you can compare the effects of market volatilities on Blueprint Medicines and Syndax Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Blueprint Medicines with a short position of Syndax Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Blueprint Medicines and Syndax Pharmaceuticals.

Diversification Opportunities for Blueprint Medicines and Syndax Pharmaceuticals

0.22

Correlation Coefficient

Blueprint Medicines  Syndax Pharmaceuticals

Modest diversification

The 3 months correlation between Blueprint and Syndax is 0.22. Overlapping area represents the amount of risk that can be diversified away by holding Blueprint Medicines Corp and Syndax Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Syndax Pharmaceuticals and Blueprint Medicines is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Blueprint Medicines Corp are associated (or correlated) with Syndax Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Syndax Pharmaceuticals has no effect on the direction of Blueprint Medicines i.e., Blueprint Medicines and Syndax Pharmaceuticals go up and down completely randomly.

Pair Corralation between Blueprint Medicines and Syndax Pharmaceuticals

Given the investment horizon of 90 days Blueprint Medicines is expected to generate 1.59 times less return on investment than Syndax Pharmaceuticals. In addition to that, Blueprint Medicines is 1.1 times more volatile than Syndax Pharmaceuticals. It trades about 0.03 of its total potential returns per unit of risk. Syndax Pharmaceuticals is currently generating about 0.06 per unit of volatility. If you would invest  1,252  in Syndax Pharmaceuticals on December 29, 2024 and sell it today you would earn a total of  104.00  from holding Syndax Pharmaceuticals or generate 8.31% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Blueprint Medicines Corp  vs.  Syndax Pharmaceuticals

Blueprint Medicines Corp

Risk-Adjusted Performance

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Blueprint Medicines Corp are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of rather unfluctuating primary indicators, Blueprint Medicines may actually be approaching a critical reversion point that can send shares even higher in April 2025.

Syndax Pharmaceuticals

Risk-Adjusted Performance

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Syndax Pharmaceuticals are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of fairly uncertain fundamental indicators, Syndax Pharmaceuticals may actually be approaching a critical reversion point that can send shares even higher in April 2025.

Pair Trading with Blueprint Medicines and Syndax Pharmaceuticals

The main advantage of trading using opposite Blueprint Medicines and Syndax Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Blueprint Medicines position performs unexpectedly, Syndax Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Syndax Pharmaceuticals will offset losses from the drop in Syndax Pharmaceuticals' long position.

The idea behind Blueprint Medicines Corp and Syndax Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.